Organization | Longeveron LLC

Longeveron LLC Report issue

For profit Phase 2

Founded: Miami FL United States (2014)

Organization Overview

First Clinical Trial

2016

NCT02600130

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Longeveron Inc. | Longeveron LLC

Active Ingredients

Drugs in Phase 2 Trials (5)

allogeneic adipose derived mesenchymal stem cell (1 trial)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

autologous mesenchymal stem cells (2 trials)

inactivated influenza vaccine (1 trial)

lomecel-b (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 1)

Frailty (Phase 2)

Hypoplastic Left Heart Syndrome (Phase 2)

Metabolic Diseases (Phase 2)

Respiratory Distress Syndrome (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial APIs: 5